NZ613299B2 - Automatic injection devices having overmolded gripping surfaces - Google Patents
Automatic injection devices having overmolded gripping surfaces Download PDFInfo
- Publication number
- NZ613299B2 NZ613299B2 NZ613299A NZ61329912A NZ613299B2 NZ 613299 B2 NZ613299 B2 NZ 613299B2 NZ 613299 A NZ613299 A NZ 613299A NZ 61329912 A NZ61329912 A NZ 61329912A NZ 613299 B2 NZ613299 B2 NZ 613299B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- housing
- gripping
- overmolded
- injection device
- automatic injection
- Prior art date
Links
- 239000007924 injection Substances 0.000 title claims abstract description 162
- 238000002347 injection Methods 0.000 title claims abstract description 157
- 238000010304 firing Methods 0.000 claims abstract description 47
- 230000001788 irregular Effects 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims description 35
- 150000002500 ions Chemical class 0.000 claims description 26
- 238000007689 inspection Methods 0.000 claims description 11
- 230000000007 visual effect Effects 0.000 claims description 5
- 108010007562 Adalimumab Proteins 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 229960002964 adalimumab Drugs 0.000 claims description 4
- 230000001808 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 description 33
- 229920001169 thermoplastic Polymers 0.000 description 13
- 239000004416 thermosoftening plastic Substances 0.000 description 13
- 229920002725 Thermoplastic elastomer Polymers 0.000 description 11
- 108090001123 antibodies Proteins 0.000 description 11
- 102000004965 antibodies Human genes 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000000875 corresponding Effects 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 6
- 101710040537 TNF Proteins 0.000 description 5
- 230000002093 peripheral Effects 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ASCUXPQGEXGEMJ-GPLGTHOPSA-N [(2R,3S,4S,5R,6S)-3,4,5-triacetyloxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(4-methylanilino)oxan-2-yl]methoxy]oxan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@H]1OC[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](NC=2C=CC(C)=CC=2)O1 ASCUXPQGEXGEMJ-GPLGTHOPSA-N 0.000 description 3
- 238000004026 adhesive bonding Methods 0.000 description 3
- 230000000994 depressed Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 238000003466 welding Methods 0.000 description 3
- 229940048921 Humira Drugs 0.000 description 2
- 101700015817 LAT2 Proteins 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229940107568 Pulmozyme Drugs 0.000 description 2
- 229940116157 Regranex Drugs 0.000 description 2
- 230000001627 detrimental Effects 0.000 description 2
- 229920005669 high impact polystyrene Polymers 0.000 description 2
- 239000004797 high-impact polystyrene Substances 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- -1 poly(ethylene terephthalate) Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 239000011528 polyamide (building material) Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000000717 retained Effects 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- WUWDLXZGHZSWQZ-WQLSENKSSA-N (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- 229960003272 ASPARAGINASE Drugs 0.000 description 1
- 108010061171 Abatacept Proteins 0.000 description 1
- 229940099550 Actimmune Drugs 0.000 description 1
- 229940099983 Activase Drugs 0.000 description 1
- 108010090726 Alefacept Proteins 0.000 description 1
- 229940115115 Aranesp Drugs 0.000 description 1
- 229940094361 Arcalyst Drugs 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 229940090047 Auto-Injector Drugs 0.000 description 1
- 229940021459 Betaseron Drugs 0.000 description 1
- 229940089093 Botox Drugs 0.000 description 1
- 229940094657 Botulinum Toxin Type A Drugs 0.000 description 1
- 108010043024 Botulinum Toxins Proteins 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 102100006435 CSF3 Human genes 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 229940088949 Cinryze Drugs 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- 229940012882 Elaprase Drugs 0.000 description 1
- 229940053603 Elitek Drugs 0.000 description 1
- 229940073038 Elspar Drugs 0.000 description 1
- 229940073621 Enbrel Drugs 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229940093738 Enzymes for ALIMENTARY TRACT AND METABOLISM Drugs 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N Epinephrine Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 229960003388 Epoetin alfa Drugs 0.000 description 1
- 229940089118 Epogen Drugs 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 229940014516 Fabrazyme Drugs 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 229960004177 Filgrastim Drugs 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100008356 IDS Human genes 0.000 description 1
- 102100005044 IL11 Human genes 0.000 description 1
- 229940090438 Infergen Drugs 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 229960003521 Interferon Alfa-2a Drugs 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 229940065638 Intron A Drugs 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- 102100011310 KLK6 Human genes 0.000 description 1
- 101700058468 KLK6 Proteins 0.000 description 1
- 229940065223 Kepivance Drugs 0.000 description 1
- 229940054136 Kineret Drugs 0.000 description 1
- 108060004843 Mical Proteins 0.000 description 1
- 229940112646 Myobloc Drugs 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 229940103023 Myozyme Drugs 0.000 description 1
- 229940068704 Naglazyme Drugs 0.000 description 1
- 229940071846 Neulasta Drugs 0.000 description 1
- 229940082926 Neumega Drugs 0.000 description 1
- 229940029345 Neupogen Drugs 0.000 description 1
- 229940024236 Nplate Drugs 0.000 description 1
- 229940100027 Ontak Drugs 0.000 description 1
- 229940035567 Orencia Drugs 0.000 description 1
- 229960002404 Palifermin Drugs 0.000 description 1
- 229940002988 Pegasys Drugs 0.000 description 1
- 229960001373 Pegfilgrastim Drugs 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 229940071643 Prefilled Syringe Drugs 0.000 description 1
- 229940087463 Proleukin Drugs 0.000 description 1
- 229960000424 Rasburicase Drugs 0.000 description 1
- 229940038850 Rebif Drugs 0.000 description 1
- 229940116243 Retavase Drugs 0.000 description 1
- 101710038979 SBXA1 Proteins 0.000 description 1
- 229960000216 Tenecteplase Drugs 0.000 description 1
- 108010039185 Tenecteplase Proteins 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 1
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 1
- 229940113038 Tnkase Drugs 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 229960004470 agalsidase beta Drugs 0.000 description 1
- 108010056760 agalsidase beta Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960002459 alefacept Drugs 0.000 description 1
- 229960004593 alglucosidase alfa Drugs 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 230000003288 anthiarrhythmic Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000023298 conjugation with cellular fusion Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940056176 drotrecogin alfa Drugs 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960005390 galsulfase Drugs 0.000 description 1
- 108010089296 galsulfase Proteins 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 108010086781 golimumab Proteins 0.000 description 1
- 229960002396 idursulfase Drugs 0.000 description 1
- 108010072166 idursulfase Proteins 0.000 description 1
- 229960003161 interferon beta-1b Drugs 0.000 description 1
- 229960002486 laronidase Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960001046 methoxy polyethylene glycol-epoetin beta Drugs 0.000 description 1
- 229960001840 oprelvekin Drugs 0.000 description 1
- 108010046821 oprelvekin Proteins 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- 229960003930 peginterferon alfa-2a Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 229920003219 poly( p-phenylene oxide) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 108010046141 rilonacept Proteins 0.000 description 1
- 229960001886 rilonacept Drugs 0.000 description 1
- 108010017584 romiplostim Proteins 0.000 description 1
- 229960004262 romiplostim Drugs 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960000103 thrombolytic agents Drugs 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 230000021037 unidirectional conjugation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150259—Improved gripping, e.g. with high friction pattern or projections on the housing surface or an ergonometric shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150274—Manufacture or production processes or steps for blood sampling devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2006—Having specific accessories
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2026—Semi-automatic, e.g. user activated piston is assisted by additional source of energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/206—With automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3125—Details specific display means, e.g. to indicate dose setting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
- A61M2205/584—Means for facilitating use, e.g. by people with impaired vision by visual feedback having a color code
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/586—Ergonomic details therefor, e.g. specific ergonomics for left or right-handed users
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
- A61M5/3137—Specially designed finger grip means, e.g. for easy manipulation of the syringe rod
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31566—Means improving security or handling thereof
- A61M5/3157—Means providing feedback signals when administration is completed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49826—Assembling or joining
Abstract
automatic injection device (100) is disclosed. The automatic injection device (100) comprises: a housing (101) enclosing a cavity for accommodating a container; a first overmolded gripping surface (154) extending longitudinally along a portion of the housing (101) on the first convex side face of the housing (101); a second overmolded gripping surface (156) extending longitudinally along a portion of the housing (101) on the second convex side face of the housing (101) opposite to the first convex side face; and a firing button (120) protruding from an aperture (126) in the housing (101). The housing (101) has a proximal portion (106) for gripping by the hand of a user and a distal portion (104) to perform an injection on the user where the proximal portion (173) has an irregular tubular shape in which a front face and an opposite back face are planar, and first and second side faces are convex. the housing (101); a second overmolded gripping surface (156) extending longitudinally along a portion of the housing (101) on the second convex side face of the housing (101) opposite to the first convex side face; and a firing button (120) protruding from an aperture (126) in the housing (101). The housing (101) has a proximal portion (106) for gripping by the hand of a user and a distal portion (104) to perform an injection on the user where the proximal portion (173) has an irregular tubular shape in which a front face and an opposite back face are planar, and first and second side faces are convex.
Description
AUTOMATIC INJECTION DEVICES HAVING
OVERMOLDED GRIPPING SURFACES
Related Applications
This application is a non-provisional of and claims priority to US. ional
Patent Application No. 61/435,465, filed January 24, 2011, the entire contents of which
are expressly incorporated herein by nce in their entirety.
Background
Automatic injection devices offer an alternative to manually-operated syringes
for administering therapeutic agents into patients’ bodies and allowing patients to self-
administer therapeutic agents. Automatic injection devices may be used to administer
medications under emergency conditions, for example, to administer epinephrine to
counteract the s of a severe allergic reaction. Automatic injection s have
also been described for use in administering anti-arrhythmic medications and selective
thrombolytic agents during a heart attack. See, for example, US. Patent Nos. 3,910,260;
4,004,577; 4,689,042; 4,755,169; and 4,795,433, the entire ts of which are
incorporated herein in their entirety by reference. Various types of automatic injection
devices are also described in, for example, US. Patent Nos. 3,941,130; 358;
,085,642; 5,092,843; 5,102,393; 5,267,963; 6,149,626; 6,270,479; and 6,371,939; and
International Patent Publication No. WO/2008/005315, the entire contents of which are
incorporated herein in their entirety by reference.
Conventionally, an automatic injection device houses a e and, when
ed, causes the syringe to move forwardly and a needle to project from the housing
so that a therapeutic agent contained in the e is d into a patient’s body.
ingly, a first aspect of the present invention provides an tic injection
device, comprising:
a housing enclosing a cavity for accommodating a container, the housing having a
al portion adapted to be gripped by the hand of a user and a distal portion adapted to
perform an injection on the user, the proximal portion having an irregular tubular shape in which
a front face and an opposite back face are planar, and first and second side faces are convex;
a first overmolded gripping e extending longitudinally along a portion of the
housing on the first convex side face of the housing;
a second overmolded gripping surface extending longitudinally along a portion of the
housing on the second convex side face of the housing opposite to the first convex side face; and
a firing button protruding from an aperture in the housing.
A second aspect of the present invention provides a method for assembling an automatic
injection device, the method comprising:
ing a housing enclosing a cavity for accommodating a container, the housing
having a proximal n d to be gripped by the hand of a user and a distal portion
adapted to perform an injection on the user, the proximal portion having an irregular tubular
shape in which a front face and an opposite back face are planar, and first and second side faces
are convex;
overmolding, on the housing, a first gripping surface extending longitudinally along a
portion of the housing on a first convex side face of the housing;
overmolding, on the g, a second gripping surface extending longitudinally along a
portion of the housing on a second convex side face of the housing opposite to the first convex
side face; and
providing a firing button within the cavity so that part of the firing button protrudes from
an aperture in the housing.
There is also disclosed herein an automatic injection device, comprising:
a g enclosing a cavity for accommodating a container, the housing comprising:
a first overmolded ng region,
a second overmolded gripping region, and
a recessed region abutting both the first and second overmolded ng regions.
Exemplary embodiments provide automatic ion devices, g components for
automatic injection devices and methods for fabricating the same. An exemplary housing of an
automatic injection device may be overmolded with one or more gripping surfaces to facilitate
ng and manipulation of the automatic injection device by a user when performing an
injection. In an exemplary ment, an lded left gripping surface may extend along a
left side of the housing and an overmolded right gripping surface may extend along a right side
of the housing opposite to the left side.
In accordance with an exemplary embodiment, an automatic injection device is provided
with a housing enclosing a cavity for accommodating a container. A first overmolded gripping
surface is provided to extend longitudinally along a portion of the housing on a first exterior
surface of the housing. A second overmolded griping surface is provided to extend
longitudinally along a portion of the housing on a second exterior surface of the g
te to the first exterior surface.
In an exemplary embodiment, the first and second overmolded gripping surfaces on the
housing are formed of a first material having a first touch perception, and nongripping surfaces
on the housing are formed of a second material having a second touch perception. In an
exemplary embodiment, the first and second overmolded gripping surfaces on the housing are
formed of a first material having a first ss, and nongripping surfaces on the housing are
formed of a second material having a second higher ss.
AH26(10402477_1):MSL
In an exemplary embodiment, the automatic injection device includes a
ble distal cap for protectively covering an injection needle couplable to the
container, an exterior surface of the distal cap including an overmolded gripping surface
for tating ng and removal of the distal cap. In an exemplary embodiment, the
automatic injection device includes a firing button protruding from an aperture in the
housing and including an overmolded contact surface for facilitating actuation of the
firing button by a user. In an exemplary embodiment, the automatic injection device
includes a al terminal end for covering a proximal end of the automatic injection
, the proximal terminal end having an overmolded exterior surface. In an
exemplary embodiment, a top surface of the al terminal end includes a recessed
surface for directing and facilitating accommodation of a user’s hand or finger for
gripping the automatic ion device.
In accordance with another exemplary ment, a method is ed for
assembling an automatic injection device. The method includes providing a housing
enclosing a cavity for accommodating a container. The method includes overmolding,
on the g, a first gripping surface extending longitudinally along a portion of the
housing on a first exterior surface of the housing. The method also includes
overmolding, on the housing, a second gripping surface ing longitudinally along a
n of the housing on a second exterior surface of the housing opposite to the first
exterior surface.
In an exemplary embodiment, the first and second gripping surfaces on the
housing are formed of a first material having a first touch perception, and non-gripping
surfaces on the housing are formed of a second material having a second touch
perception. In an exemplary embodiment, the first and second gripping surfaces on the
housing are formed of a first material having a first ss, and non-gripping surfaces
on the g are formed of a second material having a second higher hardness.
In an exemplary embodiment, the method includes overmolding a gripping
surface on an exterior surface of a distal cap to facilitate gripping and removal of the
distal cap, and ng the distal cap to a distal end of the housing for protectively
covering an injection needle. In an exemplary embodiment, the method includes
overmolding a gripping surface on a firing button to facilitate activation of the firing
button, and providing the firing button within the cavity so that part of the firing button
protrudes from an aperture in the housing.
In an exemplary embodiment, the method includes overmolding a gripping
surface on an exterior surface of a al terminal end, and coupling the proximal
terminal end to a proximal end of the housing. In an exemplary embodiment, a top
surface of the proximal terminal end includes a recessed surface for directing a user’s
hand or finger for ng the automatic injection device.
In accordance with another exemplary embodiment, an automatic ion
device is provided ing a housing enclosing a cavity for accommodating a
container. The housing includes a first overmolded gripping region, a second
overmolded gripping region, and a recessed region ng the first and second
overmolded gripping regions.
In an exemplary embodiment, the recessed region is disposed n the first
and second overmolded gripping s. In an exemplary embodiment, a Width of the
housing at the recessed region is smaller than a width of the housing at the first
overmolded gripping region and a width of the housing at the second overmolded
gripping region. In an exemplary embodiment, the recessed region lacks a gripping
surface.
In an exemplary embodiment, the first overmolded gripping region is formed by
a proximal terminal end of the housing having an exterior surface that is overmolded
with a gripping surface. In an ary embodiment, the second overmolded gripping
region of the housing has a tapered tubular structure.
Brief Description of the Drawing
The foregoing and other s, aspects, features, and advantages of exemplary
ments will become more apparent and may be better understood by referring to
the following description taken in conjunction with the accompanying drawings, in
which:
Figure l is a left side perspective view illustrating an exemplary automatic
injection device in which a removable distal cap is removed and pictured separately
from the g of the device.
Figure 2 is a right side perspective view illustrating the ary automatic
ion device of Figure 1.
Figure 3 is a left side exploded perspective view of the exemplary automatic
injection device of Figures 1 and 2.
Figure 4 is a front view of the exemplary automatic injection device of s 1-
Figure 5 is a left side View of the exemplary automatic injection device of
Figures 1-3, the right side view being a mirror image of the left side View.
Figure 6A is a front close—up view of an exemplary left gripping surface provided
on a first body portion of the device of Figures 1-3.
Figure 6B is a left side close-up view of the exemplary left gripping surface of
Figure 6A.
Figure 7 is a bottom View of an exemplary ble distal cap of the exemplary
automatic injection device of Figures 1-3.
Figure 8 is a top View of an exemplary proximal terminal end of the exemplary
automatic injection device of Figures 1—3.
Figure 9 is a flowchart of an exemplary method for forming an exemplary
automatic injection device.
Detailed Description
Exemplary embodiments e tic injection devices having housings
that are particularly designed and configured for reliable, safe, ergonomic and
comfortable handling by users. Exemplary embodiments also provide housing
components for automatic injection devices that are particularly ed and configured
for reliable, safe, ergonomic and comfortable ng by users. Exemplary
embodiments also provide methods for fabricating ary housings for automatic
injection devices and automatic injection devices including exemplary housings.
In one exemplary embodiment, one or more overmolded gripping es may
be provided on an exterior surface of an exemplary automatic injection device g
in order to allow the device to be easily, comfortably and reliably gripped and
manipulated by a user. The ary overmolded gripping surfaces are particularly
ured and positioned on the housing to prevent slippage from the hands of the user,
and thereby to avoid injury to the user and others in the vicinity. Furthermore, the
exemplary overmolded gripping surfaces are particularly configured and positioned to
be mic and comfortable to use, ularly by physically weak users, for
e, older users, users who suffer from rheumatoid arthritis, and the like.
In user tests performed using exemplary automatic injection devices, test
participants appreciated exemplary lded gripping surfaces on the sides of the
devices and the relatively large size and ergonomic shape of the . The test
participants provided high ratings for handling and grip of exemplary devices, in which
the overmolded gripping surfaces were the primary factor in test participants’ high
ratings of exemplary device configurations for handling and grip, compared to devices
without overmolded gripping surfaces. For several ity factors, there was a
significant positive correlation n Cochin scores and exemplary device
configurations, which indicates that exemplary devices are well-suited for use by users
with hand dysfunction.
An exemplary automatic injections device may contain and may be used to
administer a dose of a TNFd inhibitor. In an exemplary ment, the TNFoc
inhibitor may be a human TNFoc antibody or antigen—biding portion thereof. In an
exemplary embodiment, the human TNFa antibody or antigen—binding portion thereof
may be adalimumab (HUMIRA®) or golimumab.
I. Definitions
Certain terms are defined in this section to facilitate understanding of exemplary
embodiments.
The terms “automatic injection device” and “autoinj ector,” as used herein, refer
to a device that s a patient to dminister a therapeutically effective dose of a
eutic agent, wherein the device differs from a tional syringe by the
inclusion of a mechanism for automatically delivering the therapeutic agent to the
patient by injection when the mechanism is engaged.
The terms “vessel” and “container,” as used herein, refer to a syringe or cartridge
that may be used in an ary automatic injection device for holding a dose of a
eutic agent.
The terms “syringe” and idge,” as used herein, refer to a sterile barrel
n of an automatic injection device that is filled with a dose of a therapeutic agent
prior to distribution or sale of the device to a patient or other non-medical professional
for administration of the therapeutic agent to a patient. In an exemplary embodiment, a
distal end of the barrel portion of a syringe may be d to a sterile hypodermic
injection needle. In an exemplary embodiment, a distal end of the barrel portion of a
cartridge may not be coupled to an injection needle. That is, in exemplary embodiments,
a syringe may be a cartridge with a pre-attached injection needle coupled to its barrel
portion.
Exemplary embodiments described herein with reference to a syringe ly
may also be implemented using a cartridge assembly. Similarly, exemplary
embodiments described herein with reference to a cartridge assembly may also be
implemented using a syringe assembly.
The term “pre-filled syringe,” as used herein, refers to a syringe that is filled with
a therapeutic agent immediately prior to administration of the therapeutic agent to a
patient, and a syringe that is filled with a therapeutic agent and stored in this pre-filled
form for a period of time before administration of the therapeutic agent to a patient.
The terms “injection needle” and “needle,” as used herein, refer to a needle in an
automatic ion device that is inserted into a patient’s body to deliver a dose of a
therapeutic agent into the patient’s body. In an exemplary embodiment, the injection
needle may be directly coupled to or may otherwise be in t with a syringe
assembly or a cartridge assembly that holds a dose of the therapeutic agent. In another
exemplary embodiment, the injection needle may be ctly coupled to the syringe or
cartridge assembly, for example, via a syringe needle and/or a transfer mechanism that
provides fluid communication n the syringe or cartridge assembly and the
ion needle.
The term “pre-injection state,” as used herein, refers to a state of an automatic
injection device prior to tion of the device, i.e., prior to the start of delivery of a
therapeutic agent contained in the device.
The term “injection state,” as used herein, refers to one or more states of an
automatic injection device during the delivery of a therapeutic agent contained in the
device.
The term “post-injection state,” as used herein, refers to completion of delivery
of a therapeutically ive dose of a therapeutic agent ned in the device, or
removal of the device from the patient prior to completion of ry of a
therapeutically effective dose of the therapeutic agent.
An automatic injection device provided in accordance with exemplary
embodiments may include a “therapeutically effective amount” or a “prophylactically
effective ” of an antibody or antibody portion of the invention. A
“therapeutically effective amount,” as used , refers to an amount effective, at
dosages and for periods of time necessary, to achieve the desired therapeutic result. A
therapeutically effective amount of the antibody, antibody portion, or other TNFoc
inhibitor may vary according to factors such as the disease state, age, sex, and weight of
the patient, and the ability of the antibody, antibody portion, or other TNFoc inhibitor to
elicit a desired response in the patient. A therapeutically effective amount is also one in
which any toxic or detrimental effects of the antibody, antibody portion, or other TNFa
tor are outweighed by the eutically beneficial effects. A “prophylactically
effective amount,” as used herein, refers to an amount effective, at dosages and for
periods of time necessary, to e the desired prophylactic result. Typically, since a
prophylactic dose is used in patients prior to or at an earlier stage of disease, the
prophylactically effective amount will be less than the therapeutically effective amount.
The terms “substance” and “therapeutic agent,” as used herein, refer to any type
of drug, biologically active agent, biological substance, chemical substance or
mical substance that is capable of being administered in a therapeutically effective
amount to a patient employing exemplary automatic injection devices. Exemplary
therapeutic agents usable in exemplary tic ion s may include, but are
not limited to, agents in a liquid state. Such agents may include, but are not limited to,
adalimumab (HUMIRA®) and ns that are in a liquid solution, e.g., fusion ns
and enzymes. Examples of proteins in on include, but are not limited to,
Pulmozyme (Domase alfa), Regranex (Becaplennin), Activase (Alteplase), zyme
(Laronidase), Amevive (Alefacept), Aranesp (Darbepoetin alfa), Becaplennin
Concentrate, Betaseron (Interferon beta-1b), BOTOX (Botulinum Toxin Type A), Elitek
(Rasburicase), Elspar (Asparaginase), Epogen (Epoetin alfa), Enbrel (Etanercept),
Fabrazyme (Agalsidase beta), Infergen (Interferon n-l), Intron A (Interferon alfa-
2a), Kineret (Anakinra), MYOBLOC (Botulinum Toxin Type B), Neulasta
(Pegfilgrastim), Neumega (Oprelvekin), Neupogen (Filgrastim), Ontak (Denileukin
diftitox), PEGASYS (Peginterferon alfa-2a), Proleukin (Aldesleukin), Pulmozyme
(Domase alfa), Rebif (Interferon beta-la), Regranex lermin), Retavase
lase), Roferon-A (Interferon alfa—2), TNKase (Tenecteplase), and Xigris
(Drotrecogin alfa), Arcalyst (Rilonacept), NPlate (Romiplostim), a
(methoxypolyethylene glycol-epoetin beta), Cinryze (C1 se inhibitor), Elaprase
(idursulfase), Myozyme (alglucosidase alfa), Orencia (abatacept), Naglazyme
(galsulfase), Kepivance (palifermin) and Actimmune (interferon lb).
The term “dose” or “dosage,” as used herein, refers to an amount of a therapeutic
agent, such as a TNFor inhibitor, which is administered to a patient preferably using the
le automatic injection device of the invention. In one embodiment, the dose
ses an effective amount, for example, including, but not limited to, 20 mg, 30 mg,
40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg,
150 mg, and 160 mg, of the TNFa inhibitor adalimumab.
The term “dosing,” as used herein, refers to the administration of a therapeutic
agent (e. g., an anti-TNFO. antibody) to achieve a eutic objective (e. g., treatment of
rheumatoid arthritis).
The term “dosing regimen,” as used herein, refers to a treatment schedule for a
therapeutic agent, such as a TNFa inhibitor, e.g., a ent schedule over a prolonged
period of time and/or throughout the course of treatment, e.g. administering a first dose
of a TNFO. tor at week 0 followed by a second dose of a TNFa inhibitor on a
biweekly dosing regimen.
The term “treatment,” as used herein, refers to therapeutic treatment, as well as
prophylactic or ssive measures, for the treatment of a er, such as a disorder
in which TNFd is detrimental, e.g., rheumatoid arthritis.
The term “patient” or “user,” as used herein, refers to any type of , human
or non-human, that may be administered a therapeutic agent using exemplary tic
injection devices.
The term “proximal” refers to a portion or end or component of an exemplary
automatic injection device that is st from an injection site on a patient’s body when
the device is held against the patient for an injection or for mimicking an injection.
The term “distal” refers to a portion or end or component of an exemplary
automatic injection device that is closest to an injection site on a patient’s body when the
device is held against the patient for an injection or for mimicking an injection.
The term “planar” is used herein, in a broad lay sense, to mean exactly planar or
approximately planar within some tolerance from the exactly .
The term “concave” is used herein, in a broad lay sense, to mean exactly concave
or approximately concave within some tolerance from the exactly concave.
The term “convex” is used herein, in a broad lay sense, to mean exactly convex
or approximately convex within some tolerance from the exactly convex.
The term “elliptical” is used , in a broad lay sense, to mean exactly
elliptical or approximately elliptical within some tolerance from the exactly elliptical.
The term “oval” is used herein, in a broad lay sense, to mean exactly oval or
approximately oval within some tolerance from the exactly oval.
The term “rectangular” is used herein, in a broad lay sense, to mean exactly
rectangular or approximately rectangular within some tolerance from the exactly
rectangular.
The term “parallel” is used herein, in a broad lay sense, to mean exactly parallel
or approximately parallel within some tolerance from the exactly parallel.
The term “straight” is used herein, in a broad lay sense, to mean y straight
or approximately straight within some tolerance from the exactly straight.
The term “equal” is used herein, in a broad lay sense, to mean exactly equal or
approximately equal within some nce.
The term “adjacent” is used herein, in a broad lay sense, to mean immediately
nt or approximately nt within some nce.
The term “abut” is used herein, in a broad lay sense, to mean immediately
abutting or approximately abutting within some tolerance.
The term “transverse axis” is used herein to refer to an axis that is substantially
perpendicular to a longitudinal axis.
II. Exemplary Embodiments
ary embodiments are bed below with reference to certain
illustrative embodiments. While exemplary embodiments are described with respect to
using an automatic injection device to provide an injection of a dose of a therapeutic
agent, one of ordinary skill in the art will recognize that exemplary embodiments are not
limited to the illustrative embodiments and that exemplary automatic injection devices
may be used to inject any suitable eutic agent into a patient. In addition,
components of exemplary automatic injection devices and methods of making and using
exemplary automatic injection s are not limited to the illustrative embodiments
described below.
Figures 1-8 illustrate an exemplary automatic injection device 100 having one or
more overmolded ng surfaces for facilitating gripping and lation of the
device. The figures indicate a longitudinal axis L that runs substantially along the length
of the device 100, a first transverse axis H that runs substantially perpendicular to the
longitudinal axis L of the device, and a second erse axis V that runs substantially
perpendicular to both longitudinal axis L and first transverse axis H.
In some exemplary embodiments, an exemplary length of the device 100 may be
about 4, 4.5, 4.8, 5, 5.5, 6, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.5, 8, 8.5, 9, 9.5, 10 , but is
not limited to these exemplary lengths. In some exemplary embodiments, an exemplary
width of the device 100 (at its widest on) may be about 0.5, 0.6, 0.7, 0.8, 0.9, 1.0,
1.1, 1.2, 1.3, 141.5, 1.6, 1.7,1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0
inches, but is not limited to these exemplary widths. In some exemplary embodiments,
an exemplary ess of the device 100 (at its thickest location) may be about 0.1, 0.2,
0.3,0.4,0.5,0.6,0.7,0.8,0.9,1.0,1.1,1.11,1.12,1.13,1.14,1.15,1.16,1.17,1.18,
1.19,1.2,1.3,1.4,1.5,1.6,1.7,1.8,1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0
inches, but is not limited to these exemplary thicknesses. In an exemplary embodiment,
the device 100 may have an ary length of about 6.69 inches, an exemplary width
of about 1.46 inches at the widest portion, and an exemplary thickness of about 1.15
inches at the thickest portion. In another exemplary embodiment, the device 100 may
have an exemplary length of about 4.8 inches, an exemplary width of about 0.8 inches at
the widest portion, and an exemplary thickness of about 0.6 inches at the thickest
portion. The exemplary dimensions of the recited exemplary s allow the device to
be conformably and ergonomically held in the grip of a user’s hand. This allows a user
to reliably and tably grip and manipulate the device in order to perform an
injection.
ary tic ion device 100 may include an outer housing 101 for
housing a container, such as a syringe or cartridge. The container may be pre-filled with
a dose of a therapeutic agent to be injected into a patient’s body. The housing 101 of the
device, in its assembled form, may have any suitable size and shape for storing and
dispensing the dose of the therapeutic agent. The assembled housing 101 may have a
shape that is designed and configured to be conformable to a user’s hand and so that the
user can comfortably and reliably hold the device 100 during an ion. In an
exemplary embodiment, the assembled housing 101 may have an elongated structure so
that its length taken along the longitudinal axis L is much r than its Width taken
along the first transverse axis H and its thickness taken along a second transverse axis V.
An exemplary ratio of the length to the width (at the widest location) of the device may
be, but is not limited to, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, all intermediate ratios,
and the like. An exemplary ratio of the length to the thickness (at the thickest location)
of the device may be, but is not limited to, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, all
intermediate ratios, and the like.
Figure 1 is a left side perspective View illustrating an exemplary automatic
injection device 100 having an outer housing 101. Figure 2 is a right side perspective
View of the exemplary automatic injection device 100 of Figure 1. In an exemplary
embodiment, the g 101 of the device 100 may have a tapered tubular structure
with a substantially elliptical or oval cross—section. In the tapered tubular structure, the
width of the housing 101 may be larger at a proximal portion 106 of the housing 101
than at a distal n 104 of the housing 101. The tapered tubular shape of the
exemplary housing allows the device to be streamlined and to be mably and
ergonomically held in and manipulated by a user’s hand.
The housing 101 of the device 100 may be formed of a plurality of body
components that are assembled together. In an exemplary embodiment, the housing 101
may be formed from a first body portion 116 and a second body portion 118 that, when
cooperatively engaged to each other along their peripheral edges, enclose and provide a
cavity therebetween. The first and second body portions may be cooperatively engaged
to each other using any suitable technique ing, but not limited to, bonding, gluing,
ultrasonic welding, friction fit, snap fit, interference fit, screws, attachment between
corresponding sions and recesses, and the like. One of ordinary skill in the art will
recognize that, in other exemplary ments, the cavity of the device may be
enclosed in a single body component or in three or more body components when
assembled er.
A firing button 120 may extend from a surface of the first body portion 116. The
firing button 120, when activated by a user, may cause an injection to be performed by
the device 100. In an exemplary embodiment, a recessed or concave portion 126 may be
ed on the first body portion 116 abutting the firing button 120 to facilitate
activation of the firing button 120. The recessed portion 126 may surround the firing
button 120 in an exemplary embodiment to accommodate a user’s finger as the user
presses on the firing button 120.
A transparent inspection window 128 may be provided in a surface of the first
body portion 116 to allow a user to View the contents of the device 100. The transparent
inspection window 128 may allow the user to view a therapeutic agent contained in the
device 100, for e, to ensure clarity of the agent, and to view an end-of—injection
indicator that materializes at the end of a successful injection. An exemplary inspection
window 128 may be ntially elongated in shape, for example, an elongated
rectangle (with sharp or rounded , an elongated elliptical shape, and the like,
although other shapes are possible. In the elongated inspection window 128, the length
extending along the longitudinal axis L may be substantially greater than the width
extending along the first transverse axis H. In exemplary embodiments, a ratio between
the length and the width of the inspection window may include, but is not limited to,
15:1, 20:1, 25:1, 3.011, 3.5:1, 4.021, 4.5:1, 5:1, all intermediate ratios, and the like.
A proximal terminal end 172 of the device housing may be ed to cover the
proximal end of the device 100. In an exemplary embodiment, the al terminal
end 172 may be coupled to the proximal end of the assembled first and second body
portions. The proximal terminal end 172 may take any le size and shape. In an
ary embodiment, the proximal terminal end 172 may have a substantially tubular
configuration with a substantially oval or elliptical shape. In an exemplary embodiment,
at least part of the exterior e of the proximal terminal end 172 may be overmolded
with one or more gripping es 173 to facilitate gripping of the proximal portion of
the device. In an exemplary embodiment, the entire exterior surface of the proximal
terminal end 172 may be covered by an overmolded ng surface 173.
Corresponding recesses may be provided on the exterior surface of the proximal
terminal end 172 to accommodate the gripping surfaces.
A removable distal cap 164 may be coupled to the distal end of the assembled
first and second body portions to cover the distal end of the device 100 in order to
prevent exposure of the injection needle prior to an injection. The distal cap 164
protects against accidental andfor ed contact of a user with the injection needle.
The distal cap 164 also protects against damage to and contamination of the injection
needle when the device is not in use. The distal cap 164 may take any suitable size and
shape. In an exemplary embodiment, the distal cap 164 may have a substantially tubular
configuration with a substantially oval or elliptical shape. In an exemplary embodiment,
a front surface of the distal cap 164 may have a e cutout portion 168 for
accommodating part of the inspection window 128.
In an exemplary embodiment, the or surface of the distal cap 164 may lack
overmolded gripping surfaces. In other exemplary embodiments, the exterior surface of
the distal cap 164 may be overmolded with one or more gripping surfaces 165 for
facilitating gripping and removal of the distal cap 164 from the device. In an exemplary
embodiment, the entire exterior surface of the distal cap 164 may be covered by an
overmolded gripping e 165. Corresponding recesses may be provided on the
exterior surface of the distal cap 164 to accommodate the gripping surfaces.
In an exemplary embodiment, one or more ridges (that protrude from the exterior
surface) and/or one or more grooves or divots (that are depressed into the exterior
surface) may be provided at the gripping surfaces 165 on the distal cap 164 to further
facilitate gripping and manipulation of the device. The shapes and ons of the
ridges and/or grooves may be altered as desired, and any desired number of ridges
and/or grooves may be provided. In an exemplary embodiment, the ridges and/or
grooves may extend substantially perpendicularly to the longitudinal axis L of the
. In an exemplary embodiment, the gripping surfaces 165 may include textured
es to improve the e feel and further facilitate firm gripping of the device. In
an exemplary embodiment, the distal cap 164 may include one or more sions 170a,
170b (shown in Figure 5) that extend dly from the front e and the back
surface of the distal cap 164 to further facilitate gripping of the cap 164.
In an exemplary embodiment, the distal cap 164 may frictionally engage a
recessed or stepped portion of the housing in order to be retained in position on the
housing when the device is not in use. In an exemplary ment, the distal cap 164
may include a boss for locking and/or joining the cap to the housing until the user is
ready to perform an injection. Any suitable mating mechanism may be used in
accordance with the teachings of exemplary embodiments.
When the proximal terminal end 172, the first body portion 116 and the second
body portion 118 are assembled together, they form a tapered tubular structure. Side
surfaces of the body ns 116, 118 abutting the gripping surfaces 173 on the
proximal terminal end 172 may include one or more recessed or concave portions 122,
124. In an ary embodiment, two recessed portions 122, 124 may be provided at
opposite sides of the device abutting the firing button 120. The recessed portions allow
the hand of the user to be accommodated in a comfortable position when pressing the
firing button 120.
A portion of the body portions 116, 118 abutting the recessed portions 122, 124
may be overmolded with one or more gripping surfaces 154, 156 to facilitate holding
and manipulation of the device. In an exemplary embodiment, two gripping surfaces
154, 156 may be provided at opposite side surfaces of the device. A first ng
surface 154 may abut a first recessed n 122, and a second gripping surfaces 156
may abut a second recessed portion 124. Corresponding recesses may be provided on
the or surface of the first body portion 116 to odate the gripping surfaces.
In an exemplary housing for an automatic injection device, a first overmolded
gripping region, a second overmolded ng region and a recessed region abutting the
first and second overmolded gripping regions may be provided. The first overmolded
gripping region, the second lded gripping region and the recessed region may
cooperatively provide an ergonomic and comfortable gripping area at which a user may
grip the automatic injection device in order to perform an injection.
In this exemplary embodiment, the first overmolded gripping region may be
formed by the proximal terminal end 172 having an overmolded outer surface or
covering. The second overmolded gripping region may be formed part of the assembly
of the first body portion 116 and the second body portion 118 having one or more
overmolded gripping surfaces (for example, gripping surfaces 154, 156). In an
exemplary embodiment, the second overmolded gripping region may have a
substantially tapered tubular structure for providing an mic fit with a user’s hand.
The recessed region abutting the first and second overmolded gripping regions may be
formed by a portion of the assembly of the first body n 116 and the second body
portion 118 that is narrower in width than the first lded gripping region and the
second overmolded gripping region. In an exemplary embodiment, the recessed region
may be ed between the first and second overmolded gripping regions. In an
exemplary embodiment, the recessed region may lack any lded gripping
surfaces.
Figure 3 illustrates an exploded view of the exemplary tic injection device
100 of Figures 1 and 2. In an exemplary embodiment, the first body portion 116 may
e a substantially planar front surface (extending ntially along the L-H plane)
and left and right side surfaces (extending substantially along the L-V plane). The front
e of the first body portion 116 may contiguously and integrally transition to left
and right side surfaces of the first body portion 116. The edges at which the front
surface transitions to the side surfaces may be sharp, or smooth and rounded in order to
maintain a streamlined shape of the device and for ergonomic handling of the device.
The front and/or side surfaces of the first body portion 116 may be substantially flat or
slightly convex so that the assembled housing ergonomically fits within a user’s hand.
The front surface may be wider at the proximal portion 106 of the device than at the
distal portion 104. One of ordinary skill in the art will recognize that other exemplary
shapes are possible for the first body portion 116 of the device.
In an exemplary embodiment, the second body portion 118 may include a
substantially planar front surface (extending substantially along the L-H plane) and left
and right side surfaces (extending substantially along the L-V plane). The front surface
of the second body portion 118 may contiguously and integrally transition to left and
right side surfaces of the second body n 118. The edges at which the front surface
transitions to the side es may be sharp, or smooth and rounded in order to maintain
a streamlined shape of the device and for ergonomic handling of the device. The front
and/or side surfaces of the second body portion 118 may be substantially flat or slightly
convex so that the assembled housing ergonomically fits within a user’s hand. The front
surface may be wider at the proximal portion 106 of the device than at the distal portion
104. One of ordinary skill in the art will ize that other exemplary shapes are
possible for the second body portion 118 of the .
As illustrated in Figure 3, the first body portion 116 and the second body n
118 may be cooperatively engaged to each other along their peripheral edges to enclose
and e a cavity 102 therebetween. The upper and second body portions may be
cooperatively engaged to each other using any suitable technique including, but not
limited to, bonding, gluing, ultrasonic welding, friction fit, snap fit, interference fit,
screws, attachment between corresponding protrusions and recesses, and the like. One
of ordinary skill in the art will recognize that, in other exemplary embodiments, the
cavity 102 of the device may be enclosed in a single body component or in three or more
body components when assembled together.
An exemplary container 160 is preferably slidably positioned in the cavity 102
and is coupled to an injection needle (not shown) at a distal end. The injection needle
may be covered by a needle shield 162, for example, a soft needle shield and/or a rigid
needle shield. A container advancement mechanism may be provided within the
housing to mechanically advance the ner 160 within and relative to the housing
and to eject the therapeutic agent from the container 160 for performing an injection.
The container advancement ism may include one or more actuators (e.g., one or
more biasing members) that move the container from a sheathed on to a projecting
position. When the device is in a pre—injection state, the container 160 may be in a
ed position, i.e., retracted within the housing. When the device is actuated, the
container ement ism may advance the container 160 to a projecting
position so that the injection needle projects from a distal end of the housing to allow
ejection of the therapeutic agent into a patient’s body. The distal end of the housing may
include an aperture through which the needle may t.
The cavity 102 within the housing may also accommodate a firing engagement
mechanism, for example, the firing button 120. The firing button 120, when actuated by
sing, activates the container advancement mechanism that, in turn, es the
container 160 toward the injection site, drives the injection needle into the injection site
and delivers the therapeutic agent into the ion site. In an exemplary embodiment,
at least a portion of the exterior surface of the firing button 120 may be overrnolded with
one or more rubberized ng surfaces to facilitate pressing of the firing button by a
user’s finger or hand. In an exemplary embodiment, the entire exterior surface of the
firing button may be covered by an overmolded ng surface. In an exemplary
embodiment, the gripping surfaces on the firing button 120 may be colored differently
from the non-gripping surfaces to provide a visual affordance to indicate which area of
the device should be gripped. For example, the one or more gripping surfaces on the
firing button 120 may be green, while all other surfaces on the device may be one or
more colors that are not green.
Figure 3 shows that a front surface of the first body portion 116 may e a
first aperture 119 through which the firing button 120 may protrude outside the front
surface. An exemplary aperture 119 may be circular to accommodate the firing button
120 with a circular cross-section, although other shapes are possible. The front surface
of the first body portion 116 may e a second aperture 127 for accommodating the
transparent inspection window 128.
As rated in Figure 3, in an exemplary embodiment, the removable distal cap
164 may onally engage a recessed or stepped portion 166 of the housing in order to
be retained in position on the housing when the device is not in use.
Figure 4 illustrates a front surface of the first body portion 116 of the exemplary
automatic injection device 100. Figure 5 illustrates a left side View of the first body
portion 116 and the second body portion 118 as assembled in the device 100.
As illustrated in Figure 4, an exemplary automatic injection device 100 may have
a tapered tubular shape with a ntially elongated, elliptical cross-section. The
al terminal end 172 of the device may have a narrower proximal end (width wl)
that broadens slightly and gradually to a larger width (width w2) at the distal end of the
proximal al end 172. The proximal end of the first body portion 116 abutting the
proximal terminal end 172 may include one or more ed portions 122, 124 at the
sides. The recessed portions 122, 124 may create a narrow necked portion (width w3)
that is narrower than the adjacent width (width W2) of the proximal terminal end 172.
At the distal end of the recessed ns 122, 124, the first body portion 116 may widen
to the largest width of the device (width W) and may gradually taper to a narrower width
(width w4) near the mid-portion of the device. At the distal portion 104 of the device,
the first body portion 116 may have a substantially uniform narrow width (width w4).
The second body portion 118 may have a ntially similar shape and configuration
as the first body portion 116. As illustrated in Figure 5, in an exemplary embodiment,
the removable distal cap 164 may include one or more protrusions 170a, 170b (shown in
Figure 5) that extend outwardly from the front surface and the back surface of the distal
cap 164 to further facilitate gripping of the distal cap.
One of ordinary skill in the art will ize that other shapes are possible in
exemplary automatic injection device 100.
As illustrated in Figures 4 and 5, in an exemplary embodiment, a left gripping
surface 130 may be provided to partly cover and extend across the left side surface of
the first body portion 116, and a right gripping e 132 may be provided to partly
cover and extend across the right side surface of the first body n 116. In an
exemplary embodiment, each gripping surface 130, 132 may be disposed between the
firing button 120 and the inspection window 128. One of ordinary skill will recognize
that other placements of the gripping surfaces 130, 132 are possible. rly, in an
exemplary embodiment, a left gripping surface 152 may be provided to partly cover and
extend across the left side surface of the second body portion 118, and a right gripping
surface 153 may be provided to partly cover and extend across the right side e of
the second body portion 118. When the first and second body portions are assembled,
the left gripping surfaces 130, 152 may form a contiguous left gripping surface 154 on
the housing, and the right gripping surfaces 132, 153 may form a uous right
gripping surface 156 on the housing. The left and right contiguous gripping surfaces
154, 156 facilitate reliable and comfortable gripping and manipulation of the device by a
user’s hand, which markedly and singly improves the user ence of
physically weak users, for example, older users and users suffering from toid
arthritis .
In user tests performed using exemplary automatic injection devices, test
participants liked the overmolded gripping surfaces on the sides of the device, the ridges
on the overmolded gripping surfaces, and the relatively large size and ergonomic shape
of the device. Most test ipants (58%) strongly preferred the handling and grip of
an example automatic injection device of the present invention. l, the example
device configuration received a high average rating of 8.1 out of 10.0. The lded
ng surfaces were the primary factor in the participants’ high ratings of the example
device for handling and grip. For several usability factors, there was a significant
positive correlation between Cochin scores and the example device of the present
invention with the overmolded gripping surfaces, which indicates that the example
device of the present invention is well—suited for those with hand dysfunction.
One of ordinary skill in the art will recognize that the left and right gripping
surfaces may have different sizes, shapes and configurations than the exemplary sizes,
shapes and configurations shown in Figures 1—8. One of ordinary skill in the art will
recognize that more or fewer gripping surfaces may be provided on exemplary automatic
injection devices that the exemplary left and right gripping surfaces shown in Figures 1-
8. One of ordinary skill in the art will also recognize that one or more gripping surfaces
may be positioned on exemplary automatic injection devices in positions other than the
ary positions shown in Figures 1—8. Further, one of ordinary skill in the art will
recognize that the outline of each gripping surface may have a smooth, rounded,
streamlined configuration in some exemplary embodiments.
The overmolded gripping es provided in exemplary embodiments may be
formed of any suitable material that provides a first soft and riction touch
perception to a user, as compared to the portions of the device that lack an overmolded
gripping e which provide a second hard and low-friction touch perception to a
user. The difference in the y perceptions provides a touch affordance to a user,
indicating that the device is to be d at regions provided with the overmolded
gripping surfaces.
In an exemplary embodiment, the overmolded gripping surfaces may be formed
of a first type of al having a soft, high—friction touch tion to a user, while
the portions of the device lacking lded ng surfaces may be formed of a
second type of material having a harder, lower-friction touch perception to a user. In an
exemplary embodiment, the overmolded gripping surfaces may be formed of a first
material with a lower hardness, while the non-gripping surfaces may be formed of a
second material with a higher hardness.
For example, the non-gripping surfaces may be formed of any rigid
thermoplastic material or rigid substrate suitable for use in a medical device application
and suitable for providing a hard, low-friction touch perception to the user. Rigid
thermoplastics can include materials such as polypropylene (PP), polyethylene (PE),
yrene (PS), high impact polystyrene (HIPS), polycarbonate (PC), acrynitrile—
butadiene-styrene (ABS), poly(ethylene terephthalate) (PET), polyamide (PA), PC/ABS
blend and PPO/PS blends.
Exemplary overmolded ng surfaces may be formed of materials having any
suitable material grade and hardness for providing a soft, high-friction touch perception
to the user. Exemplary overmolded gripping surface als may include, but are not
limited to, rubber (for example, having a durometer of 50A in one embodiment),
thermoplastic elastomers (TPEs), thermoplastic vulcanizate (TPV), and the like.
Exemplary thermoplastic elastomers that may be used to form exemplary overmolded
gripping surfaces include, but are not limited to, TPEs from KRAIBURG, the
DynaflexTM TPE from PolyOne, the VersaflexTM TPE from PolyOne, the lanTM
TPE from e, the TM TPE from Polyone, and the like. Exemplary
thermoplastic vulcanizates that may be used to form exemplary overmolded gripping
surfaces include, but are not d to, the SantopreneTM thermoplastic from
ExxonMobil and the like.
In an ary embodiment, the overmolded gripping surfaces may be colored
differently from the non-gripping surfaces to provide a visual affordance to indicate
which area of the device should be d. For example, the left and right overmolded
gripping surfaces may be maroon in color while the ipping surfaces on the
housing may be grey in color.
As illustrated in Figure 5, in an exemplary embodiment, one or more ridges (that
protrude from the or e) and/or one or more grooves or divots (that are
depressed into the exterior surface) 158a, 158b, 158c (as illustrated in Figures 5 and 6B)
may be provided at the left overmolded gripping surface 154 and/or the right
overmolded gripping surface 156 to further facilitate gripping and manipulation of the
device. The shapes and locations of the ridges and/or grooves may be altered as desired,
and any desired number of ridges and/or grooves may be provided. In an exemplary
embodiment, the ridges andx’or s may extend substantially perpendicularly to the
longitudinal axis L of the device. In an exemplary ment, the lded
gripping surfaces may include textured surfaces to improve the tactile feel and further
tate firm gripping of the device.
Figure 6A is a front close-up View of an exemplary left overmolded gripping
surface 130 provided on a first body portion 116 of the device 100 of Figure 1. Figure
6B is a left side close-up view of the exemplary left lded gripping surface 130 of
Figure 6A. The right overmolded gripping surface 132 of the first body portion 116, the
left overmolded gripping surface 152 of the second body portion 118, and the right
overmolded gripping surface 153 of the second body portion 118 may be similar in
structure and configuration
Referring to Figures 6A and 6B, the left overmolded gripping e 130 may
have a first longitudinal side 134 that extends on the front surface of the first body
portion 116 substantially along the longitudinal axis L. In an exemplary embodiment,
the first longitudinal side 134 of the left overmolded gripping surface 130 may be
ntially linear, While in another exemplary embodiment, the first longitudinal side
134 may be slightly concave or convex. A proximal end 136 of the first longitudinal
side 134 may extend toward and t with an end 138 of a first horizontal side 140 of
the left overmolded gripping surface 130. The first horizontal side 140 may extend
across the left side surface of the first body portion 116 substantially along the second
transverse axis V, ending at the peripheral edge of the first body portion 116.
In an exemplary embodiment, a connecting side 142 extending n ends
136, 138 may connect the first longitudinal side 134 to the first horizontal side 140. In
an exemplary embodiment, the first horizontal side 140 may include a beveled edge
extending to the first longitudinal side 134 at an angle to both longitudinal axis L and the
first transverse axis H.
In an exemplary embodiment, the first longitudinal side 134 of the left
lded gripping surface 130 may be substantially longer than the first horizontal
side 140. An exemplary ratio of the length of the first longitudinal side 134 to the length
of the first ntal side 140 may include, but is not limited to, about 2:1, 2.5:1, 3: 1,
3.5:1, 4:1, 4.5:1, 5:1, all intermediate ratios, and the like.
A distal end 144 of the first longitudinal side 134 may extend toward and
t with an end 146 of a second horizontal side 148 of the left overmolded gripping
surface 130. In an exemplary embodiment, a connecting side 150 extending between the
ends 144, 146 may connect the first longitudinal side 134 to the second horizontal side
148. In an exemplary embodiment, the connecting side 150 may have a length greater
than that of the connecting side 142. In exemplary embodiments, a ratio of the length of
the connecting side 150 to the length of the connecting side 142 may include, but is not
d to, 1.5:1, 1.75:1, 2:1, 2.25:1, 2.5:1, 2.75:1, 3:1, 3.25:1, 3.5:1, 3.75:1, 4:1, all
intermediate , and the like, but is not limited to these exemplary . The second
horizontal side 148 may extend across the left side surface of the first body portion 116
substantially along the second transverse axis V, ending at the peripheral edge of the
first body portion 116.
In an exemplary embodiment, the first udinal side 134 may be substantially
longer than either the first ntal side 140 or the second horizontal side 148. An
exemplary ratio of the length of the first longitudinal side 134 to the length of either
horizontal side may include, but is not limited to, about 2: 1, 25:1, 3: 1, 35:1, 4:1, 4.5:1,
:1, 5.5:1, 6:1, 6.5:1, 7:1, all intermediate , and the like.
Figure 7 is a bottom View of an ary removable distal cap 164 showing the
overmolded gripping surface 165. The overmolded gripping surfaces 165 may be
formed of any suitable al that provides first a soft and high-friction touch
perception to a user, as compared to the portions of the device that lack an overmolded
gripping surface which provide a hard and low—friction touch perception to a user. The
difference in the y perceptions provides a touch affordance to a user, ting
that the device is to be gripped at regions provided with the overmolded gripping
surfaces.
In an ary embodiment, the overmolded gripping surfaces may be formed
of a first type of material having a soft, high-friction touch perception, While the non-
gripping surfaces are formed of a second type of material having a harder, lower-friction
touch perception. Exemplary overmolded gripping surfaces 165 may be formed of
materials having any suitable material grade and hardness for providing a soft, high-
friction touch perception to the user. Exemplary overmolded gripping surface als
may include, but are not limited to, rubber (for example, having a durometer of 50A in
one embodiment), thermoplastic elastomers (TPES), thermoplastic vulcanizate (TPV),
and the like. Exemplary thermoplastic elastomers that may be used to form exemplary
overmolded gripping surfaces e, but are not limited to, TPEs from KRAIBURG,
the DynaflexTM TPE from PolyOne, the VersaflexTM TPE from PolyOne, the
VersollanTM TPE from PolyOne, the OnFlexTM TPE from Polyone, and the like.
Exemplary thermoplastic vulcanizates that may be used to form exemplary lded
gripping surfaces include, but are not limited to, the SantopreneTM thermoplastic from
ExxonMobil and the like. In an ary embodiment, the overmolded gripping
surfaces 165 may be colored differently from the non-gripping es to provide a
visual affordance to indicate which area of the device should be gripped. For example,
the one or more overmolded gripping surfaces 165 on the distal cap 164 may be maroon
in color while the ipping surfaces on the housing may be grey in color.
Figure 8 is a top view of an exemplary proximal al end 172 for covering
the proximal end of the housing. In an exemplary embodiment, the exterior surface of
the proximal terminal end 172 may lack any overmolded gripping surfaces. In other
ary embodiments, at least part of the exterior surface of the proximal terminal
end 172 may be overmolded with one or more gripping surfaces 173 to facilitate
ng of the proximal portion of the device. In an exemplary embodiment, the entire
exterior surface of the proximal terminal end 172 may be covered by an overmolded
gripping surface 173.
The overmolded gripping surfaces 173 may be formed of any le material
that provides a first soft and high-friction touch perception to a user, as compared to the
portions of the device that lack an overmolded gripping e which provide a second
soft and low-friction touch perception to a user. The difference in the sensory
perceptions provides a touch affordance to a user, indicating that the device is to be
gripped at regions ed with the overmolded gripping surfaces.
In an exemplary embodiment, the overmolded gripping surfaces 173 may be
formed of a first type of material having a soft, riction touch perception, While the
non-gripping surfaces are formed of a second type of material having a harder, lower-
friction touch perception. Exemplary overmolded gripping surfaces 173 may be formed
of materials having any suitable material grade and hardness for providing a soft, high-
friction touch perception to the user. Exemplary overmolded gripping surface materials
may e, but are not limited to, rubber (for example, having a ter of 50A in
one embodiment), thermoplastic elastomers (TPEs), thermoplastic vulcanizate (TPV),
and the like. Exemplary thermoplastic mers that may be used to form exemplary
overmolded gripping surfaces include, but are not limited to, TPEs from KRAIBURG,
the exTM TPE from PolyOne, the VersaflexTM TPE from PolyOne, the
VersollanTM TPE from PolyOne, the OnFlexTM TPE from Polyone, and the like.
Exemplary thermoplastic vulcanizates that may be used to form exemplary overmolded
gripping es include, but are not limited to, the SantopreneTM thermoplastic from
ExxonMobil and the like. In an exemplary embodiment, the overmolded gripping
surfaces 173 may be colored differently from the non-gripping surfaces to provide a
visual affordance to indicate which area of the device should be gripped. For example,
the one or more overmolded gripping surfaces 173 on the proximal al end 172
may be maroon in color while the non-gripping surfaces on the housing may be grey in
color.
In an exemplary embodiment, one or more ridges (that protrude from the exterior
surface) and/or one or more grooves or divots (that are depressed into the exterior
e) may be provided on the exterior surface of the proximal terminal end 172 to
further tate gripping of the proximal portion of the device. The shapes and
locations of the ridges and/or grooves may be altered as desired, and any desired number
of ridges and/or grooves may be provided. In an exemplary embodiment, the
overmolded gripping surfaces 173 may e textured surfaces to e the tactile
feel and r facilitate firm gripping of the device. In an exemplary embodiment, a
wrap-around groove 174 may be provided around the circumference of the proximal
terminal end 172 and a concave or recessed e 176 may be provided at the top of
the proximal terminal end 172 in order to orient and guide a user’s hand and fingers to
the device. For example, the concave or recessed surface 176 may accommodate a
finger on the surface 176 while the user is performing an injection using the device.
In some exemplary ments, the housing 101, the removable distal cap 164
and/or the proximal terminal end 172 of the device 100 may further include graphics,
symbols and/or numbers to facilitate use of the automatic injection device. For example,
the distal cap 164 may include a depiction of an arrow on an outer surface pointing
towards the distal end of the device to te how the device should be held relative to
the patient (i.e., with the distal end adjacent to the ion site). One of ordinary skill
in the art will ize that the automatic injection device may have any suitable
graphics, symbols and/or numbers to facilitate patient instruction, or the automatic
injection device may omit such graphics, symbols and/or numbers.
Figure 9 is a flowchart of an exemplary method of assembling an exemplary
automatic injection device. In an exemplary embodiment, a housing of an exemplary
automatic ion device may be provided in two or more separate housing
components (for example, first and second body portion) that may be coupled together
during assembly of the device.
In step 902, a first body portion of the housing is provided or . In step
904, one or more gripping surfaces are overmolded on corresponding recesses on the
exterior surface of the first body portion to facilitate gripping and lation of the
device during an injection.
In step 906, a second body portion of the housing is provided or formed. In step
908, one or more gripping surfaces are overmolded on ponding recesses on the
exterior surface of the second body portion to facilitate gripping and manipulation of the
device during an injection.
In step 910, a proximal al end of the housing is provided or formed. In
step 912, one or more gripping surfaces are overmolded on corresponding recesses on
the exterior surface of the proximal terminal end to facilitate gripping and manipulation
of the device.
In step 914, a removable distal cap of the housing is provided or formed. In step
916, one or more gripping surfaces are overmolded on corresponding recesses on the
exterior surface of the distal cap to tate removal of the distal cap before performing
an injection.
In step 918, a firing button of the housing is provided or formed. In step 920,
one or more gripping surfaces are overmolded on the exterior e of the firing button
to facilitate activation of the firing button to perform an injection.
In step 922, one or more internal components of the automatic injection device
may be positioned in a cavity defined between the upper and second body portions.
Exemplary device components may include, but are not limited to, a container (e. g., a
syringe) pre-filled with a eutic agent for injecting into a patient, an injection
needle coupled to a distal end of the container, a container advancement ism for
advancing the container Within and relative to the g toward the injection site and
for ejecting the eutic agent from the container during an injection, a firing button
for activating the container advancement mechanism, and the like.
In step 924, the upper and second body portions may be cooperatively engaged
to form a body assembly that encloses and holds the internal components within the
cavity. In an exemplary embodiment, the body portions may be coupled at their
peripheral edges. Any suitable coupling or joining may be used in step 924 including,
but not limited to, bonding, gluing, ultrasonic welding, friction fit, snap fit, interference
fit, screws, corresponding protrusions and recesses, and the like.
In step 926, the removable distal cap may be removably coupled at a distal end
of the body assembly to cover an ion needle or a needle shield that, in turn, covers
the ion needle.
In step 928, the al terminal end may be coupled at a proximal end of the
body assembly.
Any suitable fabrication technique may be used to form any of the device
components including, but not limited to, injection g. The device components
may be formed of any suitable material including, but not limited to, cs,
thermoplastics, polycarbonates, metals, and the like.
It is noted that the order of the steps discussed herein may be altered as desired
and that other fabrication steps/techniques are le and are considered within the
spirit and scope of the present invention.
Automatic Injection Device User Tests
Forty-four test participants were recruited to test both the exemplary automatic
injection devices having overmolded ng surfaces of the present invention and four
alternate automatic injection devices without such gripping surfaces. A majority of the
participants were suffering from rheumatoid arthritis (RA) at the time of the test. The
participants were diagnosed with RA from 1 to 40 years ago, with an average age of
diagnosis of 9 years ago. Four participants were suffering from Crohn’s disease at the
time of the test.
Test ure
Each test participant tested the different exemplary automatic injection device
configurations. In particular, in an e device use phase, each test ipant
performed a simulated injection (i.e., an injection with clipped s and no
medicament) using the devices. After he/she performed a simulated ion, each test
participant was asked a series of follow-up questions designed to assess the participant’s
approval of the form and function of the devices. These ons included questions
on, for example, the size, shape, ease of handling, comfort of holding, overall user
experience, and the like.
Device Handling and Gripping
Upon performing simulated injections using the different device configurations,
test participants were asked to provide feedback and ative ratings on handling
and grip, overall ease of use, and comfort in performing the injection steps. All device
configurations were rated on a scale of 1 (very ve) to 10 (very positive).
Most test ipants (58%) strongly preferred the handling and grip of the
example device configuration of the present invention, ed to four alternate device
configurations that did not include overmolded gripping surfaces. Test participants
particularly liked the rubberized overmolded grips on the side of the example device and
its relatively large size, which made the example device easy and comfortable to hold.
The rubberized lded grips were the primary factor in participants’ high ratings of
the e device configuration for handling and grip as taught herein.
Furthermore, a correlation is was performed on hand dysfunction using the
Cochin hand disability scale with the ratings provided for certain usability factors:
handling and gripping, ease of use, ease of starting and performing an injection, comfort
of performing injection, acceptability and overall preference. For several usability
factors, there was a significant positive correlation between Cochin scores and the
example device configuration of the present invention, which indicates that this example
device configuration is well-suited for those with hand ction.
Comfort of Device Holding and Use
Upon ming simulated ions in the example device use phase, test
participants were asked to rate the comfort of holding the example device configuration
of the present invention and four alternate device configurations that did not include any
overmolded gripping surfaces. Test ipants rated each device configuration on a
scale from 1 (very low confidence) to 7 (very high confidence). Most test participants
favored the example device configuration of the present invention for comfort in
ming injection steps, with 45% rating it the highest.
Ease of Device Use and Handling
Upon initial exposure to the example device and before receiving instructions or
a demonstration on use, test participants were asked about the perceived ease of use of
the example device configuration of the t ion and four alternate device
configurations that did not include any overmolded gripping surfaces. Test ipants
rated each device configuration on a scale from 1 (very difficult) to 7 (very easy). All of
the device configurations received high ratings for their perceived ease of use.
Upon performing simulated injections in the actual device use phase, test
participants were asked to rate the ease of handling each device configuration. Test
participants rated each device configuration on a scale from 1 (very low confidence) to 7
(very high ence). Furthermore, upon performing simulated injections using the
device configuration in the third actual device use phase, test participants were also
asked to rate the configurations on their overall ease of use on a scale of 1 (very
difficult) to 10 (very easy).
Most test participants (42%) found the example device configuration of the
present ion easiest to use compared to four alternate device configurations that did
not include lded gripping surfaces. Overall, the example device configuration of
the present invention received a high average rating of 7.97 out of 10.0.
Device Size
Upon performing simulated ions in the example device use phase, test
participants were asked to rate the overall size of the example device configuration of
the present invention and four ate device configurations that did not include any
overmolded gripping surfaces on a scale of 1 (very low confidence) to 7 (very high
confidence). All of the device urations generally received positive ratings for
their overall shape. In general, test ipants who struggled to form a tight fist
preferred larger devices. The example device uration of the present invention
lly received the highest ratings.
Device Shape
Upon performing simulated injections in the actual device use phase, test
participants were asked to rate the overall shape of the example device configuration of
the present invention and four alternate device configurations that did not include any
overmolded ng surfaces on a scale of 1 (very low ence) to 7 (very high
confidence).
All of the device configurations generally received positive ratings for their
overall size. In general, test participants who struggled to form a tight fist preferred
larger devices. With respect to the example device configuration of the present
invention, many participants found that the shape fit nicely in their hand.
III. oration by Reference
The contents of all references, including patents and patent applications, cited
throughout this application are hereby incorporated herein by reference in their ty.
The appropriate components and methods of those references may be selected for the
invention and embodiments thereof. Still further, the components and methods
identified in the Background section are al to this disclosure and can be used in
conjunction with or substituted for components and methods described elsewhere in the
disclosure within the scope of the invention.
IV. Equivalents
In describing exemplary embodiments, specific terminology is used for the sake
of clarity. For purposes of description, each specific term is intended to, at least, include
all technical and functional equivalents that operate in a similar manner to accomplish a
similar e. Additionally, in some instances where a particular exemplary
embodiment includes a plurality of system elements or method steps, those elements or
steps may be replaced with a single t or step. Likewise, a single element or step
may be replaced with a plurality of elements or steps that serve the same purpose.
Further, where parameters for various properties are ied herein for exemplary
embodiments, those parameters may be ed up or down by l/20th, 1/ 10th, l/5th,
l/3rd, l/2nd, and the like, or by rounded—off approximations thereof, unless otherwise
specified. Moreover, while exemplary embodiments have been shown and described
with references to particular embodiments thereof, those of ordinary skill in the art will
understand that various substitutions and alterations in form and details may be made
therein without departing from the scope of the invention. Further still, other aspects,
ons and advantages are also within the scope of the invention.
Exemplary flowcharts are provided herein for rative purposes and are non-
limiting examples of methods. One of ordinary skill in the art will recognize that
exemplary methods may include more or fewer steps than those illustrated in the
exemplary flowcharts, and that the steps in the ary flowcharts may be med
in a different order than shown.
Claims (37)
1. An automatic injection device, comprising: a housing enclosing a cavity for accommodating a container, the housing having a proximal portion adapted to be gripped by the hand of a user and a distal portion adapted to perform an injection on the user, the proximal portion having an irregular tubular shape in which a front face and an opposite back face are planar, and first and second side faces are convex; a first overmolded gripping surface extending longitudinally along a portion of the housing on the first convex side face of the housing; a second overmolded gripping e extending longitudinally along a n of the g on the second convex side face of the housing opposite to the first convex side face; and a firing button protruding from an re in the housing.
2. The automatic injection device of claim 1, wherein the first and second overmolded gripping surfaces on the housing include one or more grooves or ridges for facilitating gripping and manipulation of the tic injection device.
3. The tic injection device of claim 1, wherein the first and second overmolded gripping surfaces on the housing are formed of a first material having a first touch perception, and non-gripping surfaces on the housing are formed of a second material having a second touch perception.
4. The automatic ion device of claim 1, wherein the first and second overmolded gripping surfaces on the g are formed of a first material having a first hardness, and nongripping surfaces on the housing are formed of a second material having a second, higher hardness.
5. The automatic injection device of claim 1, wherein the first and second overmolded gripping surfaces on the housing have a different color than non-gripping es on the housing.
6. The automatic injection device of claim 1, further comprising: a removable distal cap for protectively covering an injection needle couplable to the container, an or e of the distal cap including an overmolded gripping surface for facilitating gripping and removal of the distal cap.
7. The automatic ion device of claim 6, wherein the exterior surface of the distal cap includes one or more grooves or ridges for facilitating gripping and removal of the distal cap.
8. The tic injection device of claim 1, wherein the firing button includes an overmolded contact surface for facilitating ion of the firing button by a user.
9. The automatic injection device of claim 1, wherein the firing button is positioned along a transverse axis perpendicular to a longitudinal axis of the device.
10. The automatic injection device of claim 9, r comprising: a recessed surface provided adjacent to the firing .
11. The automatic injection device of claim 10, wherein the recessed surface is ed surrounding the firing .
12. The automatic injection device of claim 1, further comprising: a proximal terminal end for covering a proximal end of the automatic injection device, the proximal terminal end having an overmolded exterior surface.
13. The automatic injection device of claim 12, wherein a top surface of the proximal terminal end includes a recessed surface for directing and facilitating gripping of the automatic ion device.
14. The automatic injection device of claim 1, further comprising: a transparent inspection window disposed in the housing to allow inspection of the ts of the container.
15. The automatic ion device of claim 14, wherein, at the end of an injection, the inspection window is filled with a visual indicator.
16. The automatic injection device of claim 1, wherein the proximal portion of the device is configured for ergonomic and reliable gripping by the hand of the user.
17. The automatic ion device of claim 1, wherein the first and second overmolded gripping surfaces are disposed at the proximal portion of the device and extend across portions of the first and second side faces.
18. The automatic injection device of claim 1, wherein the housing comprises a plurality of housing components cooperatively engaged to define the cavity therein.
19. The automatic injection device of claim 1, wherein the container holds a dose of a TNF inhibitor.
20. The automatic injection device of claim 19, wherein the TNF inhibitor is adalimumab.
21. A method for assembling an automatic injection device, the method comprising: providing a housing enclosing a cavity for accommodating a container, the housing having a proximal portion adapted to be gripped by the hand of a user and a distal portion d to perform an injection on the user, the al portion having an irregular r shape in which a front face and an opposite back face are planar, and first and second side faces are convex; overmolding, on the housing, a first gripping surface extending longitudinally along a portion of the housing on a first convex side face of the housing; overmolding, on the housing, a second ng surface extending udinally along a n of the housing on a second convex side face of the housing te to the first convex side face; and providing a firing button within the cavity so that part of the firing button protrudes from an aperture in the housing.
22. The method of claim 21, n the first and second gripping surfaces on the housing include one or more grooves or ridges for facilitating gripping and manipulation of the automatic injection device.
23. The method of claim 21, wherein the first and second gripping surfaces on the housing are formed of a first material having a first touch perception, and non-gripping surfaces on the housing are formed of a second material having a second touch perception.
24. The method of claim 21, wherein the first and second gripping surfaces on the g are formed of a first material having a first hardness, and non- gripping surfaces on the housing are formed of a second material having a second, higher hardness.
25. The method of claim 21, further comprising: overmolding a gripping surface on an exterior surface of a distal cap to facilitate gripping and removal of the distal cap; and ng the distal cap to a distal end of the housing for protectively covering an ion needle.
26. The method of claim 25, wherein the exterior surface of the distal cap includes one or more grooves or ridges for facilitating gripping and removal of the distal cap.
27. The method of claim 21, further comprising: overmolding a gripping surface on the firing button to facilitate activation of the firing button.
28. The method of claim 21, n the firing button is positioned along a transverse axis perpendicular to a longitudinal axis of the device.
29. The method of claim 28, further comprising: forming a recessed surface abutting the firing button.
30. The method of claim 29, wherein the recessed surface is provided surrounding the firing button.
31. The method of claim 21, further comprising: overmolding a gripping surface on an exterior surface of a al terminal end; and coupling the proximal terminal end to a proximal end of the housing.
32. The method of claim 31, wherein a top surface of the proximal terminal end es a recessed surface for facilitating gripping of the automatic injection device.
33. The tic injection device of claim 1, further comprising: a first concave n disposed in the first convex side face of the housing proximate to the first overmolded gripping surface; and a second concave portion ed in the second convex side face of the housing proximate to the second overmolded gripping surface.
34. The method of claim 21, r comprising: forming a first concave portion disposed in the first convex side face of the housing proximate to the first overmolded gripping surface; and forming a second concave portion disposed in the second convex side face of the housing proximate to the second overmolded gripping surface.
35. The automatic injection device of claim 33, wherein the first concave portion is disposed between the first overmolded gripping e and a proximal terminal end of the housing and the second concave portion is disposed between the second overmolded ng surface and the al terminal end of the housing.
36. The method of claim 34, n the first concave portion is disposed in the first exterior surface of the housing between the first overmolded gripping surface and a proximal terminal end of the housing and the second concave portion is disposed in the second exterior surface of the housing between the second overmolded gripping surface and the al terminal end of the housing.
37. An automatic injection device, substantially as hereinbefore described with reference to any one of the embodiments as that ment is shown in the accompanying drawings. AbbVie Biotechnology Ltd. By the Attorneys for the Applicant SPRUSON & FERGUSON Per: REPLACEMENT SHEET 168 100 164 165 Distal n 104 116 128 156
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ711444A NZ711444B2 (en) | 2011-01-24 | 2012-01-24 | Housing for an automatic injection device having overmolded gripping surfaces |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161435465P | 2011-01-24 | 2011-01-24 | |
US61/435,465 | 2011-01-24 | ||
PCT/US2012/022433 WO2012103141A1 (en) | 2011-01-24 | 2012-01-24 | Automatic injection devices having overmolded gripping surfaces |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ613299A NZ613299A (en) | 2016-02-26 |
NZ613299B2 true NZ613299B2 (en) | 2016-05-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230158243A1 (en) | Automatic injection devices having overmolded gripping surfaces | |
EP2244768B1 (en) | Device for injecting apportioned doses of liquid drug | |
JP2022177159A (en) | Palm-activated drug delivery device | |
NZ613299B2 (en) | Automatic injection devices having overmolded gripping surfaces | |
NZ739694B2 (en) | Automatic injection devices having overmolded gripping surfaces | |
NZ722287B2 (en) | Automatic injection devices having overmolded gripping surfaces | |
NZ711444B2 (en) | Housing for an automatic injection device having overmolded gripping surfaces |